Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Bayer Aktiengesellschaft (OTCMKTS:BAYRY) have earned an average rating of “Moderate Buy” from the eight research firms that are presently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, four have issued a buy recommendation and two have assigned a strong buy recommendation to the company.

BAYRY has been the topic of several research analyst reports. Zacks Research lowered Bayer Aktiengesellschaft from a “strong-buy” rating to a “hold” rating in a research report on Monday, February 23rd. Morgan Stanley raised Bayer Aktiengesellschaft from an “equal weight” rating to an “overweight” rating in a report on Wednesday, December 3rd. DZ Bank lowered shares of Bayer Aktiengesellschaft from a “strong-buy” rating to a “strong sell” rating in a research report on Wednesday, February 18th. Barclays raised shares of Bayer Aktiengesellschaft from an “equal weight” rating to an “overweight” rating in a report on Tuesday, January 6th. Finally, JPMorgan Chase & Co. upgraded shares of Bayer Aktiengesellschaft from a “neutral” rating to an “overweight” rating in a research report on Monday, December 8th.

Bayer Aktiengesellschaft Stock Performance

Shares of BAYRY stock opened at $10.99 on Friday. The stock’s 50-day moving average is $12.47 and its two-hundred day moving average is $10.03. The firm has a market cap of $43.19 billion, a price-to-earnings ratio of -9.90 and a beta of 0.69. Bayer Aktiengesellschaft has a 1 year low of $5.30 and a 1 year high of $14.85. The company has a debt-to-equity ratio of 1.10, a quick ratio of 0.71 and a current ratio of 1.14.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) last posted its earnings results on Wednesday, March 4th. The company reported $0.18 EPS for the quarter, hitting analysts’ consensus estimates of $0.18. The business had revenue of $13.24 billion for the quarter, compared to analysts’ expectations of $13.08 billion. Bayer Aktiengesellschaft had a positive return on equity of 15.35% and a negative net margin of 8.51%.Bayer Aktiengesellschaft has set its FY 2026 guidance at 1.251-1.400 EPS. Analysts predict that Bayer Aktiengesellschaft will post 1.31 earnings per share for the current year.

Bayer Aktiengesellschaft Company Profile

Bayer Aktiengesellschaft is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields.

In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women’s health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates.